Results 301 to 310 of about 742,288 (358)
Some of the next articles are maybe not open access.
Cardiovascular adjustment to antiadrenergic agents
The American Journal of Medicine, 1983A common target organ involvement associated with essential hypertension is left ventricular hypertrophy. A number of, but not all, effective antihypertensive drugs will regress left ventricular hypertrophy. Our attention has focused on the hemodynamic characteristics of those drugs that either directly or indirectly alter sympathetic nervous activity.
B L, Pegram, E D, Frohlich
openaire +2 more sources
Quinazoline cardiovascular agents (review)
Pharmaceutical Chemistry Journal, 1982The chemistry of quinazoline compounds has a more than centuries-old history; however, the intensive search for biologically active substances in this series began only in the last few decades. The establishment of the quinazoline structure of the antimalarial alkaloid febrifugine [i], which was isolated from the Chinese plant aseru (Dichroa febrifuga ...
O. N. Volzhina, L. N. Yakhontov
openaire +1 more source
Oral Antidiabetic Agents and Cardiovascular Outcomes
Current Problems in Cardiology, 2018Cardiovascular disease is the leading cause of morbidity and mortality among patients with type 2 diabetes; however, a direct protective effect of tight glycemic control remains unproven. In fact, until 2008, when concerns related to rosiglitazone prompted regulatory agencies to mandate assessment of cardiovascular safety of new antidiabetic agents ...
Pareek, Manan, Bhatt, Deepak L
openaire +3 more sources
Seminars in dialysis, 2011
With a growing population of patients with chronic kidney disease (CKD), it is critical that clinicians are aware of the consequences of how kidney failure affects the pharmacokinetics and pharmacodynamics of cardio- vascular medications. This is particularly true in patients on chronic hemodialysis. Approximately 30% of medication-related prob lems in
Walton, Ted, Thomas, Rebekah
openaire +1 more source
With a growing population of patients with chronic kidney disease (CKD), it is critical that clinicians are aware of the consequences of how kidney failure affects the pharmacokinetics and pharmacodynamics of cardio- vascular medications. This is particularly true in patients on chronic hemodialysis. Approximately 30% of medication-related prob lems in
Walton, Ted, Thomas, Rebekah
openaire +1 more source
Infective Agents and Cardiovascular Disease
Seminars in Vascular Medicine, 2002As a consequence of seminal laboratory and experimental work conducted in the 1970s, infections have recently been recognized among possible risk factors for atherosclerosis and its clinical cardiovascular disease manifestations. The infectious hypothesis also relates to modern atherogenesis theories that consider the crucial role of inflammation in ...
openaire +2 more sources
Oral antidiabetic agents as cardiovascular drugs
Diabetes, Obesity and Metabolism, 2006The increased risk of cardiovascular disease associated with type 2 diabetes is well documented. Lesser degrees of abnormal glucose metabolism including impaired fasting glycaemia and impaired glucose tolerance are also associated with increased cardiovascular risk.
D P, Macfarlane +2 more
openaire +2 more sources
Antiplatelet agents in cardiovascular disease
Journal of Thrombosis and Thrombolysis, 2011Despite improvements in the treatment of acute coronary syndromes (ACS), cardiovascular disease remains the leading cause of death in the United States. Antiplatelet agents, such as aspirin and clopidogrel, play an important role in the treatment of patients with ACS, particularly those at high risk for whom treatment may yield the greatest benefits ...
openaire +2 more sources